|Bid||20.05 x 800|
|Ask||27.80 x 900|
|Day's Range||20.45 - 21.27|
|52 Week Range||11.93 - 26.10|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
AMAG Pharmaceuticals (AMAG) needs investors to pay close attention to the stock based on moves in the options market lately.
Investors betting on Tesla’s stock stumbling took a beating this week when shares in the company rallied after CEO Elon Musk tweeted that he was considering taking the company private.
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -257.14% and -6.90%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 58 cents. Losses, adjusted to account for discontinued operations, were 75 cents per share. The results fell short of ...
Moody's Investors Service ("Moody's") assigned a B3 Corporate Family Rating (CFR) to GI Chill Acquisition LLC (doing business as California Cryobank Life Sciences) At the same time, Moody's assigned a B3-PD Probability of Default Rating (PDR) and a B2 rating to the company's new first lien senior secured term loan and revolver. Proceeds from the debt issuance, along with equity and a new second lien term loan (not rated), will be used in part to fund the acquisition and combination of California Cryobank and Cord Blood Registry by private equity firm, GI Partners. GI Chill's B3 Corporate Family Rating reflects Moody's view that the company will operate with high debt/EBITDA of more than 8.5 times on a GAAP basis (more than 6.5 times if adjusting for deferred revenues related to pre-paid subscriptions) over the next 12-18 months.
The Waltham, Massachusetts-based company said it had a loss of $1.59 per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
I am going to run you through how I calculated the intrinsic value of AMAG Pharmaceuticals Inc (NASDAQ:AMAG) using the discounted cash flow (DCF) method. Anyone interested in learning aRead More...
AMAG Pharma (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Waltham, Massachusetts-based company said it had profit of 10 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Moody's Investors Service says a supplemental regulatory approval of AMAG Pharmaceuticals, Inc.'s ("AMAG") next generation Makena drug-device combination product is credit positive. The approval ...
What Led to Stellar Rise of AMAG Pharmaceuticals in February? AMAG Pharmaceuticals (AMAG) is a biopharmaceutical company with a focus on clinical research and the development of therapeutics. AMAG also provides services for preserving umbilical cord stem cells and cord tissue units through cord blood registry.
Amag increased its value by nearly a third Thursday after U.S. regulators approved a second drug from the biotech this month.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shares are skyrocketing Thursday as the company received regulatory approval for one of its treatments. The company announced that the U.S. Food and Drug Administration gave the green light for its Makena subcutaneous auto injector drug-device combination product, which is a treatment that is designed to reduce the risk of preterm birth in women who are pregnant with one baby, as well as those who spontaneously delivered one preterm baby in the past. AMAG Pharmaceuticals developed the medication along with Antares Pharma Inc (NASDAQ:ATRS) as the two companies agreed back in a 2014 deal that AMAG will make and supply the drug product to Antares.